Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Monday

Neumora Therapeutics (NASDAQ:NMRA) is projected to issue its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:30 PM ET.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). On average, analysts expect Neumora Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Neumora Therapeutics Price Performance

Shares of Neumora Therapeutics stock traded down $0.02 during trading on Monday, reaching $2.43. The company’s stock had a trading volume of 93,050 shares, compared to its average volume of 1,608,003. The company has a quick ratio of 5.87, a current ratio of 5.87 and a debt-to-equity ratio of 0.52. Neumora Therapeutics has a 12-month low of $0.61 and a 12-month high of $3.65. The company has a market capitalization of $443.02 million, a P/E ratio of -1.67 and a beta of 3.02. The business has a 50 day moving average price of $2.58 and a 200-day moving average price of $2.38.

Analysts Set New Price Targets

A number of analysts recently weighed in on NMRA shares. Mizuho set a $6.00 price target on Neumora Therapeutics in a research note on Monday, January 5th. Guggenheim restated a “buy” rating and issued a $14.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, March 31st. Needham & Company LLC restated a “buy” rating and issued a $8.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, March 31st. William Blair upgraded Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 17th. Finally, Leerink Partners assumed coverage on Neumora Therapeutics in a research report on Monday, January 12th. They set an “outperform” rating and a $8.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Neumora Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.67.

Insider Buying and Selling at Neumora Therapeutics

In other news, insider Paul L. Berns sold 9,819 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $3.51, for a total value of $34,464.69. Following the completion of the transaction, the insider directly owned 7,395,185 shares of the company’s stock, valued at $25,957,099.35. The trade was a 0.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold 23,387 shares of company stock valued at $82,647 over the last ninety days. Insiders own 26.94% of the company’s stock.

Hedge Funds Weigh In On Neumora Therapeutics

Institutional investors have recently made changes to their positions in the stock. Hsbc Holdings PLC acquired a new position in shares of Neumora Therapeutics in the fourth quarter worth $27,000. Virtu Financial LLC acquired a new position in shares of Neumora Therapeutics in the third quarter worth $31,000. Fred Alger Management LLC acquired a new position in Neumora Therapeutics in the fourth quarter valued at $40,000. Canada Pension Plan Investment Board acquired a new position in Neumora Therapeutics in the second quarter valued at $41,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Neumora Therapeutics in the third quarter valued at $44,000. 47.65% of the stock is owned by institutional investors and hedge funds.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.